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Highlights 
 Comparing serum levels of multiple vitamin D metabolites, only 
3-epi-25(OH)D3 was significantly lower in patients with rheumatoid arthritis 
(RA) compared with healthy controls 
 In RA serum, 25(OH)D3 correlated with serum 3-epi-25(OH)D3, 1,25(OH)2D3 
and 24,25(OH)2D3 
 In RA all vitamin D metabolites were significantly lower in synovial fluid [2] 
compared to serum  
 Only SF 25(OH)D3 and 3-epi-25(OH)D3 correlated with RA disease activity 
markers   
 
Abstract 
Vitamin D-deficiency has been linked to inflammatory diseases including rheumatoid 
arthritis (RA). Studies to date have focused on the impact of serum 25-hydroxyvitamin 
D3 (25(OH)D3), an inactive form of vitamin D, on RA disease activity and progression. 
However, anti-inflammatory actions of vitamin D are likely to be mediated at sites of RA 
disease, namely the inflamed joint, and may involve other vitamin D metabolites 
notably the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). In the 
current study serum and synovial fluid samples from n=20 patients with persistent RA 
and n=7 patients with reactive arthritis (ReA) were analysed for multiple vitamin D 
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metabolites. Serum data for RA and ReA patients were compared to healthy controls 
(HC). There was no significant difference between RA or ReA patients relative to HC 
for 25(OH)D3, 24,25(OH)2D3, 1,25(OH)2D3 or 25(OH)D2. However, 3-epi-25(OH)D3 
was significantly lower in RA and ReA patients compared to HC (p<0.05). All vitamin D 
metabolites, apart from 25(OH)D2, were lower in SF compared to serum, and SF 
1,25(OH)2D3 was unquantifiable in 13/20 RA and 4/7 ReA samples. SF 25(OH)D3, 
3-epi-25(OH)D3 and DBP correlated inversely with swollen joint score, and serum 
25(OH)D2 and SF DBP correlated directly with C-reactive protein levels. These data 
indicate that serum 25(OH)D3 provides only limited insight into the role of vitamin D in 
RA. Alternative serum metabolites such as 3-epi-25(OH)2D3, and SF metabolites, 
notably lack of SF 1,25(OH)2D3, may be more closely linked to RA disease severity 
and progress.       
 
 
Keywords: Vitamin D; rheumatoid arthritis; synovial fluid; serum; inflammatory 
disease; vitamin D binding protein; free vitamin D  
 
 
1. Introduction 
In addition to its established actions as a regulator of mineral homeostasis and bone 
metabolism, vitamin D has been reported to promote potent immunomodulatory 
responses including the induction of innate antibacterial [3], and adaptive 
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anti-inflammatory, tolerogenic adaptive [4] immunity. Studies ex vivo suggest that the 
proposed immunomodulatory actions of vitamin D are mediated via metabolism of 
precursor 25-hydroxyvitamin D3 (25(OH)D3) to active 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) by antigen-presenting cells (APC) such as macrophages [5] and 
dendritic cells [6]. The resulting localized synthesis of 1,25(OH)2D3 may then fulfill 
endogenous, intracrine, functions such as enhanced antibacterial responses [7, 8] or 
suppression of antigen-presentation [6, 9, 10]. However, APC-derived 1,25(OH)2D3 
may also function in a paracrine fashion by acting on activated T lymphocytes (T cells) 
that express the nuclear vitamin receptor (VDR), and which show anti-inflammatory, 
tolerogenic responses to 1,25(OH)2D3 [11-14]. The over-arching role of vitamin D 
within the immune system therefore appears to be to combat infection, whilst 
suppressing potentially detrimental inflammation that may be associated with infection 
or inappropriate activation by self-antigens.  
 
The role of vitamin D as a regulator of immune function has also been studied in vivo. 
Mice with knockout of the gene for VDR (Vdr KO) [15] or the vitamin D-activating 
enzyme 1α-hydroxylase (Cyp27b1) [16] show increased severity of colitis in mouse 
models of inflammatory bowel disease (IBD) colitis. Vdr KOs also shows aggravated 
inflammatory disease in murine models of rheumatoid arthritis (RA) [17]. Likewise, 
mice that are vitamin D-deficient (low serum 25(OH)D3) show increased murine colitis 
[18] and experimental autoimmune encephalomyelitis [19]. In humans, vitamin 
D-deficiency has been linked to increased risk and disease severity for autoimmune 
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diseases such as multiple sclerosis [20], type 1 diabetes [21], IBD [22], and RA [23-25].  
 
RA is a systemic inflammatory disease characterised by the symmetrical onset of 
multiple painful swollen joints, eventually leading to permanent joint destruction, loss of 
mobility and increased risk of mortality [26]. Clinically the diagnosis of RA is defined by 
the points-based EULAR Classification Criteria; these include measurements of 
c-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and the tender/swollen 
joint count (TJC/SJC).  This cumulative scoring system defines a score of ≥6 as a 
definitive diagnosis for RA.  In contrast to RA, Reactive Arthritis (ReA) is an acute 
form of inflammatory joint arthritis often triggered as a secondary response to 
gram-negative bacterial infection [27, 28]. Unlike RA the diagnosis of ReA is based on 
clinical features such as swollen joints, as opposed to measurements of inflammatory 
markers in blood. Elimination of bacterial infection requires the activation of T-helper 
(Th) 1 cells and the release of associated pro-inflammatory cytokines IFN-γ and TNF-α, 
triggering secondary inflammation as seen in ReA [29]. 
 
Despite the observed links between vitamin D-deficiency and autoimmune disease, a 
causative role for vitamin D-deficiency in the onset and severity of inflammatory 
disease is still not clear. In RA, some studies have demonstrated a link between low 
vitamin D in early stage RA and subsequent disease progression [25], whilst others 
have not [30]. In common with other inflammatory diseases, the impact of vitamin D on 
RA has been assessed primarily via the measurement of serum levels of 25(OH)D3, 
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although this is not an active metabolite. The aim of the current study was therefore to 
firstly determine whether other vitamin D metabolites, including 1,25(OH)2D3, may be 
more informative in defining RA disease. The study also involved analysis of paired 
synovial fluid samples to assess the relationship between tissue-specific 
concentrations of vitamin D metabolites and associated serum levels. The third aim of 
the study was to assess the impact of the serum carrier protein, vitamin D binding 
protein (DBP), on serum and SF vitamin D function with respect to RA disease activity.       
 
2. Materials and methods  
2.1 Patients 
Matched serum and synovial fluid samples from n=20 patients with active rheumatoid 
arthritis (RA) and n=7 patients with resolving reactive arthritis (ReA) were obtained 
with patient consent according to existing ethical agreements. Both RA and ReA 
patients had arthritis and active inflammation at the time of presentation and sample 
collection in clinic.  RA patients continued to have ongoing inflammatory disease 
whereas ReA patients had a form of reactive arthritis that spontaneously resolved. 
Patients were assessed for various disease activity markers including erythrocyte 
sedimentation rate (ESR), c-reactive protein (CRP), and the 28 joint tender joint count 
(TJC) and swollen joint count (SJC) [31]. Disease-free age-matched subjects were 
used as healthy control (HC) group for serum analyses. RA and ReA patient 
demographics are shown in full in Table 1, and Supplemental Table 1 for healthy 
controls.      
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2.2 Quantification of serum and SF vitamin D metabolites  
Liquid-chromatography tandem mass-spectrometry (LC-MS/MS) was used to quantify 
the following vitamin D metabolites in serum and SF; 25(OH)D3, 3-Epi-25(OH)D3, 
25(OH)D2, 24,25-dihydroxyvitamin D3 (24,25(OH)₂D3) and 1,25(OH)₂D3 as 
described previously [32-34] with slight modifications. In brief, samples were prepared 
for analysis by protein precipitation and supported liquid-liquid extraction, followed by 
derivatization with 
4-(2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl)-1,2,4-triazoline-3,5
-dione (DMEQ-TAD) as previously described [35]. Analysis of extracted sera and SF 
vitamin D metabolites was performed on a Waters ACQUITY ultra performance liquid 
chromatography (UPLC) coupled to a Waters Xevo TQ-XS mass spectrometer. The 
LC-MS/MS method has been validated on US Food and Drug Administration 
guidelines for analysis of these metabolites. 
  
2.3 Quantification of vitamin D binding protein and albumin, and estimation of 
free and bioavailable 25(OH)D3 
Vitamin D binding protein (DBP) and albumin were quantified in RA and ReA serum 
and SF using VDBP (Immunodiagnostik, Bensheim, Germany) and Human Serum 
Albumin ELISA kits (Thermo Fisher, Runcorn, UK) respectively.  All reagents supplied 
were diluted to the appropriate concentrations as stated in the manufacturers’ 
protocols and all steps were carried out at room temperature. Serum and SF 
concentrations of ‘free’ (not bound to any serum protein) and ‘bioavailable’ (not bound 
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to DBP) 25(OH)D were estimated using values for total 25(OH)D, DBP and albumin, 
and mathematical algorithms adapted from the original calculations [36, 37].          
 
2.4 Statistics 
All statistical analyses were carried out using GraphPad PRISM Version 6.07 software 
(San Diego, CA, USA). Normality was assessed using D’Agostino-Pearson omnibus 
normality test, with multifactorial data compared using either one-way ANOVA 
(parametric) or Kruskal-Wallis test (non-parametric) based on ranks, with Tukey or 
Dunn’s method used as for post hoc multiple-comparison procedures respectively.  
 
3. Results 
3.1  Serum vitamin D metabolites in RA and healthy controls 
Data in Figure 1 showed that of the vitamin D metabolites analysed, only 
3-epi-25(OH)D3 was significantly different in serum from RA (median 0.788 ng/ml, 96% 
confidence limits 0.573-0.997, p<0.01) and ReA (median 0.361 ng/ml, 98% confidence 
limits 0.197-1.69, p<0.05) patients relative to healthy controls (HC) (median 1.17 ng/ml, 
97% confidence limits 0.832-1.59). Data for serum vitamin D metabolites in RA, ReA 
and HC were unaffected by donor gender, age, or duration of disease (data not shown). 
Serum concentrations of 25(OH)D3 for RA patients showed strong correlation with 
other serum vitamin D metabolites, apart from 25(OH)D2 which showed a trend to 
inverse correlation with 25(OH)D3 (Supplemental Figure 1).  
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3.2  Serum versus SF vitamin D metabolites in RA and ReA 
With the exception of 25(OH)D2, all vitamin D metabolites showed significantly lower 
concentrations in SF vs paired serum from RA patients (Figure 2A). However, only SF 
25(OH)D3 and 3-epi-25(OH)D3 showed significant correlation with serum levels of the 
same metabolites (Figure 2B). Furthermore, in contrast to RA serum vitamin D 
metabolite data, only 3-Epi-25(OH)D3 showed correlation with 25(OH)D3 in SF 
(Supplemental Figure 1). In patients with ReA, 25(OH)D3, 25,25(OH)2D3 and 
1,25(OH)2D3 were statistically lower in SF vs paired serum (Supplemental Figure 
2A), while only 25(OH)D3 and 24,25(OH)₂D3 in ReA SF correlated significantly with 
the same metabolites in serum (Supplemental Figure 2B).    
 
Figure 1. Rheumatoid arthritis and the serum vitamin D metabolome. 
Serum from n=20 persistent RA (RA) patients, n=7 reactive arthritis (ReA) patients and 
n=23 healthy controls (HC) were analysed by LC-MS/MS for: 25(OH)D3 (ng/mL); 
3-epi-25(OH)D3 (ng/mL); 25(OH)D2 (ng/mL); 24,25(OH)₂D3 (ng/mL); 1,25(OH)₂D3 
(pg/mL). Data shown are mean ± SD. * = significantly different HC vs RA, p<0.05, ** 
p<0.01. Mann-Whitney T-test for unpaired samples was performed for statistical 
analysis. 
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Figure 2. Serum vs SF vitamin D metabolites in patients with persistent RA. 
Comparison of serum and synovial fluid [2] concentrations for: 25(OH)D3; 
3-epi-25(OH)D3; 25(OH)D2; 24,25(OH)2D3 (ng/mL); 1,25(OH)2D3 (pg/mL).  B) 
Correlation of serum and SF concentrations for: 25(OH)D3; 3-epi-25(OH)D3; 
25(OH)D2; 24,25(OH)2D3 (all ng/mL); 1,25(OH)2D3 (pg/mL). n=20 matched for serum 
and SF (One-way ANOVA).  Linear regression was performed by best-fit values ± SD. 
Coefficient of determination (r2) values are shown for correlations that were statistically 
significant, p < 0.05.  
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3.3 DBP, albumin and free vs bioavailable serum and SF vitamin D 
Concentrations of DBP were significantly lower in RA SF (median 33 µg/ml, 95% 
confidence limits 24.37-43.19) and ReA SF (median 35.82, 95% confidence limits 
19.25-77.98) relative paired serum for RA (median 117 µg/ml, 95% confidence limits 
95.38-149.8, p<0.001) and ReA (median 85.66, 95% confidence limits 68.48-103.1, 
p=0.0156) patients (Figure 4). Albumin concentrations were also significantly lower in 
RA SF (median 1.423 g/dL, 95% confidence limits 1.398-1.712) vs paired serum 
(median 2.22 g/dL, 95% confidence limits 2.054-2.602, p=0.0005). 
 
Figure 3. DBP, albumin and free versus bioavailable 25(OH)D in serum and SF   
Serum and SF from n=20 RA and n=7 ReA patients were used to measure 
concentrations of DBP and albumin, and calculate free (not bound to DBP or albumin) 
and bioavailable (not bound to DBP) 25(OH)D.  Data shown are mean ± SD. 
Statistical significance = *p<0.05; **p<0.01; *** p<0.001; ****p<0.0001.  Wilcoxon 
matched-pairs signed rank test was performed for matched serum vs SF samples.  
Mann-Whitney unpaired t-test was performed for non-matched samples.   
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Based on DBP and albumin levels and total 25(OH)D3 values it was possible to 
calculate free 25(OH)D3 (not bound to DBP or albumin) and bioavailable 25(OH)D3 
(not bound to DBP) for serum and SF samples. These values showed no significant 
difference between RA and ReA serum. Furthermore, in contrast to the decreased total 
serum 25(OH)D3 observed for SF versus serum (see Figure 1), free 25(OH)D3 levels 
were significantly higher in RA SF compared to RA serum (p=0.0046). Bioavailable 
25(OH)D3 showed no significant variations in RA vs ReA for either serum or SF 
(Figure 3).   
 
3.4  Vitamin D metabolites, DBP, albumin and disease activity in RA 
Specific vitamin D metabolite concentrations were studied in relation to measures of 
RA disease activity. Significant correlations are shown in Figure 4. In SF, 25(OH)D3 
and 3-epi-25(OH)D3 correlated inversely with swollen joint score (SJC), which also 
correlated inversely with SF DBP levels. However, serum 25(OH)D2 correlated directly 
with serum levels of c-reactive protein (CRP), and serum 25(OH)D2 also correlated 
with SJC. The relationship between serum or SF 25(OH)D3, 25(OH)D2, 
3-epi-25(OH)D3, 24,25(OH)₂D3 and 1,25(OH)₂D3 and markers of RA disease (CRP, 
ESR, SJC and TJC) in RA patients is shown in full in Supplemental Figures 3-6. 
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Figure 4. Correlation of RA disease markers and serum/SF vitamin D 
metabolites and DBP.     
RA disease markers with statistically significant correlations with vitamin D metabolites, 
or DBP, in serum or SF samples from RA patients. SJC (swollen joint count); CRP 
(C-reactive protein). Linear regression was performed by best-fit values ± SD. 
Coefficient of determination (r2) values are shown for correlations that were statistically 
significant, p < 0.05.  
 
Serum DBP was positively correlated with CRP and inversely correlated with SJC, only 
in the SF of RA patients (Figure 4).  None of the other disease markers showed 
significant correlation with DBP concentrations in either serum or SF (Supplemental 
Figure 7).  Albumin was not significantly correlated with any disease markers 
(Supplemental Figure 8).  
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4. Discussion 
Low serum concentrations of 25(OH)D3 have been reported to be a feature of 
inflammatory diseases such as RA [38-41], although some studies have indicated that 
the vitamin D status of RA patients is not necessarily lower than in healthy controls [40]. 
Consistent with the latter report, in the current study serum concentrations of 
25(OH)D3 were not significantly different between RA and ReA patients and healthy 
controls, although all groups showed mean values that were lower than 50 nmol/L, the 
vitamin D-sufficiency level proposed by the Institute of Medicine [42]. Notably the one 
vitamin D metabolite that was significantly lower in serum from RA and ReA patients 
relative to healthy controls was 3-epi-25(OH)D3, but the potential impact of this is 
unclear. Although 3-epi-25(OH)D3 was initially observed in serum from neonates, 
recent studies have shown that this metabolite is present in adult serum at levels which 
vary between 0 and 25% of 25(OH)D3 in the same sample [43]. The precise function of 
3-epi-25(OH)D3 in vitamin D physiology is still unclear, and interpretation of data is 
complicated by the fact that levels of this metabolite are closely linked to serum 
25(OH)D3. It is also unclear what contribution serum or SF vitamin D metabolites may 
make to the resolution of inflammatory disease in ReA patients, although it is important 
to recognize that the current study was limited by the low numbers of patients with this 
form of inflammatory arthritis.  
 
A key observation in the current study is the lower vitamin D metabolite concentrations 
in SF versus paired serum samples. For 25(OH)D3 the mean ratio of serum/SF was 
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1.74, whilst for 1,25(OH)2D3 this was 6.07. Similar observations have been reported 
previously for 25(OH)D3 [44, 45], although levels of 25(OH)D3 in serum and SF in 
these studies varied considerably. By contrast, previous analysis of 1,25(OH)2D3 in RA 
patients reported similar [46], or modestly suppressed [45] concentrations in SF 
relative to serum. One possible explanation for significantly lower levels of SF 
1,25(OH)2D3 in the current study is the use of more reliable LC-MS/MS technology for 
quantification of 1,25(OH)2D3, compared to the relatively non-specific radioreceptor 
[46] or radioimmunoassays [45] used to measure 1,25(OH)2D3 in the previous studies. 
Previous studies also reported strong correlation between serum and SF 1,25(OH)2D3, 
and between SF 25(OH)D3 and SF 1,25(OH)2D3 [45], which we did not observe in the 
current study.  
 
In common with previous studies we were unable to analyse SF from control HC 
subjects, and thus it is unclear whether decreased 1,25(OH)2D3 is a feature of SF that 
is unaffected by inflammatory disease. It is also unclear whether SF 1,25(OH)2D3 is a 
more informative marker of vitamin D function than more conventionally measured 
25(OH)D3. SF 1,25(OH)2D3 did not appear to correlate with RA disease activity, 
whereas SF 25(OH)D3, 3-epi-25(OH)D3 and DBP were all inversely related to 
inflammation markers. One challenge with the interpretation of these data is that 
measures of inflammation where at the ‘whole patient’ level (i.e. systemic inflammatory 
markers or total joint counts) rather than at the level of the individual joint from which 
synovial fluid was studied and in which levels of vitamin D metabolites were measured. 
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However, our data linking 25(OH)D3 rather than 1,25(OH)2D3 with RA inflammation 
scores would endorse the proposed intracrine model for SF metabolism of 25(OH)D3 
[47], with locally synthesized 1,25(OH)2D3 acting to promote anti-inflammatory 
responses and inhibit disease markers independent of serum 1,25(OH)2D3.  
 
The inference from previous studies is that inflammatory factors promote enhanced 
extra-renal synthesis of 1,25(OH)2D3 via immune cell activity of 1α-hydroxylase [47]. 
Based on this model, enhanced vitamin D status (higher serum levels of 25(OH)D3), 
leads to increased SF 25(OH)D3, and this in turn promotes SF production of 
1,25(OH)2D3. Data in the current study do not appear to support this mechanism, with 
SF 1,25(OH)2D3 being below the lower limit of quantification in 13/20 RA samples, and 
4/7 ReA samples. This may reflect the efficacy of the anti-inflammatory therapies 
currently used to manage RA, with several of the treatments used in the current study 
such as hydroxychloroquine being potential inhibitors of the 1α-hydroxylase enzyme 
involved in SF synthesis of 1,25(OH)2D3 [47, 48]. However, analysis of treated versus 
non-treated RA samples, including steroidal versus non-steroidal therapies, did not 
reveal any significant differences in serum or synovial fluid 25(OH)D3 or 1,25(OH)2D3 
(data not shown). It is also possible that synthesis of 1,25(OH)2D3 within SF is tightly 
regulated and limited to the immediate immune microenvironment. This would 
maximize anti-inflammatory responses to 1,25(OH)2D3, whilst limiting the potential for 
spill-over of 1,25(OH)2D3 into the general circulation.  
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As well as studying the impact of vitamin D metabolites on RA disease, serum and SF 
levels of DBP and albumin were also measured. Interestingly SF DBP correlated 
inversely with SJC. This may simply reflect the association between DBP and SF 
concentrations of 25(OH)D3, but 25(OH)D3-independent DBP activities have also 
been described, including effects as a macrophage-activation factor [49], and 
actin-binding capacity [50], that have the potential to influence RA disease-severity 
and progression. In common with most vitamin D metabolites, and consistent with 
previous publications [44], concentrations of DBP in RA and ReA were lower in patient 
SF relative to serum. We also observed lower concentrations of albumin in SF as 
previously reported [51]. The net effect of this is that calculated levels of 25(OH)D3 not 
bound to DBP or albumin (free 25(OH)D3) and 25(OH)D3 not bound to DBP 
(bioavailable 25(OH)D3) were the same for RA and ReA SF as paired serum values. 
This suggests that there is rheostatic regulation of vitamin D binding proteins in SF to 
maximize free or bioavailable 25(OH)D3, but it is important to recognise that the values 
presented in the current study are calculated estimates of unbound 25(OH)D3. We 
were unable to directly measure free 25(OH)D3 as recently described in other studies 
[52], and it is possible that other factors present in SF may significantly enhance or 
impede protein binding of 25(OH)D3. Further studies are required to determine more 
accurately the proportions of bound and unbound 25(OH)D3 in SF from RA patients. 
 
Although 25(OH)D3 has been shown to promote anti-bacterial and anti-inflammatory 
activity via intracrine or paracrine pathways involving immune cell synthesis of 
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1,25(OH)2D3, the precise mechanism by which 25(OH)D3 gains access to immune 
cells expressing 1α-hydroxylase is far from clear. Cells such as macrophages [5] and 
dendritic cells [6] express 1α-hydroxylase, but do not appear to express the DBP 
receptor megalin [53]. In this setting, synthesis of 1,25(OH)2D3, and associated 
immune function, may be dependent on macrophage uptake of 25(OH)D3 that is not 
bound to DBP (free or bioavailable 25(OH)D3) [53].  Due to the lipophilic nature of 
25(OH)D3 it is thought that its biological actions are exerted through the unbound 
25(OH)D that is able to diffuse across cell membranes – the so-called free hormone 
hypothesis [54, 55]. In the current study we were unable to demonstrate that free or 
bioavailable 25(OH)D3 are better correlates of RA disease than the more 
conventionally measured total 25(OH)D3 (data not shown). However, the fact that the 
limited inverse correlations with RA disease that we identified involved SF rather than 
serum further supports the view that circulating concentrations of vitamin D provide 
only a limited perspective on the extra-skeletal actions of vitamin D. This appears to be 
particularly true in diseases such as RA where tissue-specific levels of 25(OH)D3 may 
be crucial in defining the anti-inflammatory potential of vitamin D. 
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Gender Age 
(years) 
Duration of 
Disease 
TJC  
(28) 
SJC  
(28) 
ESR CRP VAS DAS28  
ESR 
DAS28 
CRP 
RA or ReA Medication (DMARDs, biologics, 
steroids, NSAIDs) 
 
M 40 5 years 4 4 33 35 25 7.67 7.47 RA prednisolone, etanercept 
F 19 6 months 25 7 42 28 n/a n/a n/a RA ibuprofen 
M 75 1 year 23 19 41 23 93 8.83 8.33 RA diclofenac 
F 33 1 year 6 3 19 15 78 6.68 6.58 RA nil 
F 40  16 years 0  29 0 2 5.40 4.00 RA nil 
F 56  2 years 17 4 61 8 90 9.30 8.18 RA methotrexate, hydroxychloroquine 
F 43  7 months 3 2 20 0 7 4.70 3.56 RA ibuprofen 
M 59  10 years 8 18 n/a 108 98 n/a n/a RA nil 
F 41  6 weeks 28 18 54 40 94 9.99 9.50 RA diclofenac 
F 67  6 years 5 8 86 84 49 11.6 11.0 RA methotrexate, hydroxychloroqine 
F 73  18 years 9 10 7 7 48 4.26 4.60 RA meloxicam, methotrexate 
F 68  12 weeks 6 4 97 77 n/a  n/a n/a RA diclofenac 
M 82  <1 year 5 1 35 60 70 8.95 8.90 RA nil 
M 58 1 year 5 15 12 6 n/a n/a n/a RA nil 
F 78 1 year 10 15 31 8 44 6.93 6.28 RA nil 
F 74  4 months 5 9 34 0 44 6.35 4.84 RA nil 
F 39  <1 year 11 6 81 59 98 11.6 11.0 RA nil 
M 39  4 years 1 2 28 30 16 7.05 6.92 RA prednisolone, etanercept 
F 48  16 days 8 6 4 102 16 5.14 6.80 RA diclofenac 
F 49  14 days 9 8 6 0 35 3.12 2.82 RA nil 
M 23  6 weeks 1 1 n/a 0 75 n/a n/a ReA ibuprofen 
M 23  10 weeks 1 2 2 6 n/a n/a n/a ReA diclofenac 
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M 28  10 weeks 1 2 4 0 n/a n/a n/a ReA nil 
M 18  8 weeks 1 1 33 36 n/a n/a n/a ReA diclofenac 
M 28  19 weeks 1 1 5 5 n/a n/a n/a ReA nil 
M 23  3 weeks 0 1 5 0 83 3.54 3.37 ReA ibuprofen 
M 32  7 weeks 1 1 n/a 38 n/a n/a n/a ReA diclofenac 
 
Table 1. RA and ReA patient demographics and disease scores   
Data for patients with active rheumatoid arthritis (RA) (n=20) and resolving reactive arthritis (ReA) (n=7), including age of patient, disease duration, 
and disease severity and progression markers tender joint count (TJC); swollen joint count (SJC); erythrocyte sedimentation rate (ESR); 
c-reactive protein (CRP); diagnosis and medication. DMARDs (disease-modifying anti-rheumatic drugs), NSAIDs (non-steroidal 
anti-inflammatory drugs), steroids and biological drugs taken by each patient prior to study entry are also listed. N/A refers to missing data.   
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